Published in final edited form as:

Mol Pharm. 2011 October 3; 8(5): 1495–1504. doi:10.1021/mp2002363.

Human Pluripotent Stem Cell-Based Approaches for Myocardial Repair: From the Electrophysiological Perspective

Ellen Poon^{1,#}, Chi-wing Kong^{1,2,3,#}, and Ronald A. Li^{1,2,3,4,5}

¹Stem Cell & Regenerative Medicine Consortium, LKS Faculty of Medicine, University of Hong Kong

²Heart, Brain, Hormone & Healthy Aging Research Center, LKS Faculty of Medicine, University of Hong Kong

³Department of Medicine, LKS Faculty of Medicine, University of Hong Kong

⁴Department of Physiology, LKS Faculty of Medicine, University of Hong Kong

⁵Center of Cardiovascular Research, Mount Sinai School of Medicine, New York, NY

Abstract

Heart diseases are a leading cause of mortality worldwide. Terminally differentiated adult cardiomyocytes (CMs) lack the innate ability to regenerate. Their malfunction or significant loss can lead to conditions from cardiac arrhythmias to heart failure. For myocardial repair, cell- and gene-based therapies offer promising alternatives to donor organ transplantation. Human embryonic stem cells (hESCs) can self-renew while maintaining their pluripotency. Direct reprogramming of adult somatic cells to become pluripotent hES-like cells (a.k.a. induced pluripotent stem cells or iPSCs) has been achieved. Both hESCs and iPSCs have been successfully differentiated into genuine human CMs. In this review, we describe our current knowledge of the structure-function properties of hESC/iPSC-CMs, with an emphasis on their electrophysiology and Ca^{2+} -handling, along with the hurdles faced and potential solutions for translating into clinical and other applications (e.g., disease modeling, cardiotoxicity and drug screening).

Heart disease and cell-based therapy

Circulation requires the highly coordinated efforts of chamber-specific pacemaker, atrial and ventricular cardiomyocytes (CMs), which differ in their morphological, structural and functional properties. Normal rhythms originate in the sino-atrial node (SAN), a specialized cardiac tissue consisting of only a few thousands pacemaker cells. In the process of pacing, the SAN spontaneously generates rhythmic action potentials (AP) which subsequently propagate to induce coordinated muscle contractions of the atria and ventricles for effective blood pumping. Since terminally-differentiated adult CMs lack the ability to regenerate, their malfunction due to aging or significant loss under pathophysiological conditions (e.g., myocardial infarction) can lead to consequences from arrhythmias (such as SAN dysfunction that necessitates electronic pacemaker implantation) to heart failure (primarily a disease of the ventricle). For patients with end-stage heart failure, heart transplantation remains the last resort but this option is limited by the number of donor organs available. As such, cell replacement therapy presents a laudable alternative. Various cardiac and non-cardiac lineages have been suggested as potential cell sources. Transplantable human CMs

Corresponding author: Ronald A. Li, Cardiovascular Research Center, Mount Sinai School of Medicine, Atran Berg Laboratory Building Floor 3 Room 3-22, 1428 Madison Avenue, New York, NY 10029, ronald.li@mssm.edu.

[#]these authors contributed equally.

(e.g. human fetal CMs) appear to be the most relevant but substantial practical and ethical limitations exist. Therefore, non-cardiac cells such as skeletal muscle myoblasts (SkM), mesenchymal stem cells and smooth muscle cells have been sought as potentially viable alternatives. However, the non-cardiac identity of these cell sources presented major limitations. For instance, it is now established that although bone marrow stem cells improve cardiac functions of ischemic patients by promoting angiogenesis, they lack the capacity to transdifferentiate into cardiac muscle for myocardiogenesis¹⁻². Due to the absence of conduction via gap junctions, the lack of electrical integration of SkM after their autologous transplantation into the myocardium has been shown to underlie the generation of malignant ventricular arrhythmias, which led to the premature termination of their clinical trials³⁻⁴. In this review, we will focus our discussion on human pluripotent stem cells.

Human embryonic stem cells (hESC) and induced pluripotent stem cells (iPSC)

Human embryonic stem cells, isolated from the inner cell mass of blastocyst, can self-renew while maintaining their pluripotency to differentiate into all cell types⁵, including CMs⁶⁻⁷. Therefore, in principle, hESCs can serve as an unlimited *ex vivo* source of CMs for cell-based heart therapies. Indeed, hESC-derived CMs (hESC-CMs) have been reported to partially restore impaired cardiac functions in several animal models of myocardial infarction⁸⁻⁹. However, a range of ethical and technical hurdles (e.g. immune rejection of the transplanted grafts) has vastly limited their translations into clinical applications. Direct reprogramming of adult somatic cells to become pluripotent hES-like cells (a.k.a. induced pluripotent stem cells or iPSCs) has been achieved by Yamanaka¹⁰ and Thomson¹¹, potentially eliminating both ethical concern and the issue of immune rejection. Forced expression of four pluripotency genes (Oct3/4, Sox2, c-Myc, and Klf4 or Oct3/4, Sox2, Nanog, and Lin28)¹⁰⁻¹² suffices to reprogram mouse and human fibroblasts into iPSCs. Recent studies have further demonstrated the successful use of fewer pluripotency factors¹³⁻¹⁵ and non-viral methods (e.g., with synthetic modified RNA¹⁶) to reprogram somatic cells into patient-specific iPSCs. Although concerns such as induced somatic coding mutations¹⁷ have yet to be fully addressed, iPSCs largely resemble hESCs in terms of their pluripotency, surface markers, morphology, proliferation, feeder dependence, global transcriptomic profile and epigenetic status, promoter activities, telomerase activities, and *in vivo* teratoma formation¹⁰⁻¹¹. Importantly, iPSCs can likewise be differentiated into CMs¹⁸. Adopting a similar reprogramming approach, more recent studies have reported the successful direct conversion of fibroblasts into cardiomyocytes¹⁹ although their functionality and the underlying mechanisms for such cell fate conversion require further investigations and scrutiny (see also review by Xu et al²⁰).

Cardiac differentiation

CMs originate from the mesodermal germ layer. During the course of gastrulation, cardiac progenitors migrate through the node region and primitive streak to form the cardiac crescent²¹⁻²³. At this stage, CMs become specified, along with the expression of various cardiac transcription factors. Fetal CMs continue to proliferate until they terminally exit the cell cycle a few days after birth. Further growth is accomplished via physiological hypertrophy by increasing the size rather than the number of CMs²⁴⁻²⁵. Subsequent development of CMs also involves the structural and functional maturation of their electrophysiological, Ca²⁺-handling and contractile properties. Taken collectively, the formation of the adult heart is a complex developmental event, involving the orchestrated interplay of numerous biological factors and processes.

Early studies have demonstrated that murine (m) ESCs can spontaneously differentiate into CMs when they aggregate in suspension to form 3-dimensional embryoid bodies (EBs)²⁶. Indeed, the developmental changes of mESC-derived CMs differentiated *in vitro* mimic those seen in early myocardial development *in vivo*: pacemaker-, atrial- and ventricular-like derivatives appear and predominate at early, intermediate and late stages of cardiac differentiation, respectively, although a heterogeneous population of all three CM types is almost always seen in mouse EBs. Similar to the murine counterpart, hESC (and iPSC) can be spontaneously differentiated into a composite of specialized cell types including CMs^{6–7, 27–28}. Cardiac differentiation can also be enhanced by coculture with visceral endoderm-like cells²⁹ or promoted by stage-specific induction by specific combinations of growth and transcription factors^{30–31}. Other approaches such as the use of different extracellular matrices, serum³² and insulin elimination³³ have also been pursued. Keller and colleagues (2008) have reported the specification of human tripotent KDR^{low}/c-kit^{neg} cardiovascular progenitors (CP) into CMs³⁴. Driven mesodermal differentiation results in generation of a KDR^{low}/c-kit^{neg} CP population which defines one of the earliest stages of human cardiac development. CP-containing cardiogenic EBs or “cardiospheres” derived from hESCs can efficiently differentiate into CMs *in vitro* with >50% yield, as gauged by the proportion of cells that express troponin T. Further modifications of this protocol enable the induction of a large CP population, allowing the generation of highly enriched CMs (with yields orders of magnitude higher than that the conventional method of EB formation) even without the need for cell sorting. Therefore, hESC/iPSCs can in principle provide an unlimited *ex vivo* source of CMs for disease modeling and cell-based heart therapies. However, terminal differentiation and derivation of specific CM subtypes have not yet been accomplished but are actively pursued by many laboratories, including our own. Various purification methods including Percoll gradient centrifugation⁷, optical signatures³⁵, and genetic selection based on the expression of a reporter protein under the transcriptional control of a cardiac-restricted promoter (e.g., α -MHC³⁶, MLC2v^{37–38}) have been developed to generate purer preparations of CMs.

Electrophysiology and Ca²⁺-handling as fundamental Properties of CMs

Upon *electrical* stimulation of a ventricular muscle CM by pacemaking signals, voltage-gated Na (I_{NaV}) channels open to initiate an AP, during which Ca²⁺ ions enter into the cytosol through sarcolemmal L-type Ca²⁺ (I_{Ca,L}) channels, triggering the release of Ca²⁺ from the intracellular Ca²⁺ stores (a.k.a. sarcoplasmic reticulum, SR) via ryanodine receptors (RyR). This so-called Ca²⁺-induced Ca²⁺-release (CICR)³⁹ escalates the cytosolic Ca²⁺ ([Ca²⁺]_i) to activate the contractile apparatus for *mechanical* contraction. For relaxation, elevated [Ca²⁺]_i gets pumped back into the SR by the sarco/endoplasmic reticulum Ca²⁺-ATPase (SERCA) and extruded by the Na⁺-Ca²⁺ exchanger (NCX) to return to the resting [Ca²⁺]_i level. Such a rise and subsequent decay of [Ca²⁺]_i are known as *Ca²⁺ transient*. Both the contractile force and frequency of CMs depend on the Ca²⁺ transient amplitude and kinetics. Given the central importance of CICR in excitation-contraction (EC) coupling, *proper electrophysiological and Ca²⁺ handling properties are crucial for CMs to mechanically function*. Abnormal electrophysiology and Ca²⁺ handling, as in heart failure, can be arrhythmogenic³⁹.

In mature ventricular CMs (VCMs), CICR is facilitated by the presence of t-tubules, invaginations in the sarcolemmal membrane that concentrates I_{Ca,L} channels and brings them spatially closer to RyRs residing on the SR membrane located deeper in the cytoplasm^{40–41}. By physically minimizing the diffusion distance, RyRs in CMs can participate in CICR without a lag. The result is a synchronized, faster, and greater transient [Ca²⁺]_i increase from the periphery to the center, creating a uniform Ca²⁺ wavefront across the transverse section with simultaneous recruitment of all SR. Fast and synchronized

activation of RyRs translates into a greater Ca^{2+} transient amplitude, recruitment of more actin–myosin cross-bridge cycling, and generation of greater contractile force. Such a uniform Ca^{2+} wave starkly contrasts with the U-shaped Ca^{2+} wave propagation from the periphery to the center in a de-tubulated ventricular or atrial CM (that lacks t-tubules) such as those from failing hearts⁴⁰. The U-shaped waves result from a time delay that is proportional to the diffusion distance squared in recruiting the Ca^{2+} stores at the cell center⁴².

Structural and functional properties of human ESC- and iPSC-derived CMs

Human ESC-CMs have been structurally and functionally characterized by us and several laboratories. Human ESC-CMs express cardiac-specific transcription factors and structural proteins^{6–7, 27–29}. Although all hESC lines are by definition pluripotent, we have reported that different lines have distinct cardiogenic potentials to become early ventricular-, atrial- and pacemaker-like derivatives as gauged by their signature AP profiles. For instance, HES2 cells have a higher likelihood than H1 cells of differentiating into ventricular-like hESC-CMs⁴³ (Figure 1). Using the same methods for hESCs, human iPSCs can likewise differentiate into CMs with nodal-, atrial-, or ventricular-like electrophysiological phenotypes¹⁸. The derived CMs also expressed cardiac-specific transcription factors and structural proteins⁴⁴. Positive and negative chronotropic responses can be induced by isoproterenol and carbamylcholine, respectively⁴⁴. In the two subsections that follow, we will focus our discussion on the Ca^{2+} -handling and electrophysiological properties of hESC-CMs.

Ca^{2+} -handling of hESC/iPSC-CMs is functional but immature

Dolnikov and colleagues (2006) were the first to study the Ca^{2+} -handling properties of hESC-CMs in detail⁴⁵. They reported that Ca^{2+} transients recorded from spontaneously beating or electrically stimulated hESC-CMs respond to neither caffeine nor ryanodine; hESC-CMs recorded as beating clusters also displayed a negative force-frequency relationship that is different from adult CMs. Based on these observations, the authors concluded that hESC-CMs are immature and do not express functional SRs, and that their contractions result from trans-sarcolemmal Ca^{2+} influx (rather than Ca^{2+} release from the SR). Our laboratory compared Ca^{2+} transients from hESC-CMs and human fetal left ventricular (LV) CMs (16–18 weeks) (Figure 2), and demonstrated the presence of functional SRs even in hESC-CMs that were younger (Figure 2)⁴⁶ (18–24 vs. 55-day old post-differentiation of Dolnikov et al). Upon electrical stimulation, hESC-CMs generated Ca^{2+} transients similar to fetal LV-CMs. However, caffeine-induced Ca^{2+} release was observed in 65% of fetal LV-CMs but only ~40% of H1- and HES2-CMs. Ryanodine significantly reduced the electrically-evoked Ca^{2+} transient amplitudes and slowed the upstroke of caffeine-responsive HES2- and H1-CMs but NOT caffeine-insensitive cells; thapsigargin, a SERCA inhibitor, similarly reduced the amplitude and slowed the decay of only caffeine-responsive HES2- and H1-CMs⁴⁶. The discrepancy between our findings and those of Dolnikov et al can be largely attributed to the newly identified caffeine-responsive population.

Human ESC-CMs and adult CMs display different expression patterns of Ca^{2+} handling proteins. For instance, NCX protein expression is highest in hESC-CMs, and fetal LV-CMs compared to adult LV-CMs. The same trend is also observed at the functional level³⁸. By contrast, SERCA2a is highest in adult LV-CMs, although it is also substantially and comparably expressed in hESC- and fetal LV-CMs. RyRs is robustly expressed in hESC-CMs and fetal LV-CMs but in disorganized manner compared to adult LV-CMs. The regulatory proteins junctin, triadin, and calsequestrin (CSQ) are expressed in adult LV-CMs but are completely absent in hESC-CMs⁴⁶. Similarly, phospholamban (PLN) is also not

expressed. Additionally, hESC-CMs do not display t-tubules (Figure 3)⁴⁷ that facilitate CICR. Table 1 summarizes some Ca^{2+} -handling properties of hESC-, fetal and adult CMs.

While Ca^{2+} -handling proteins including $\text{I}_{\text{Ca,L}}$ channels, RyR, SERCA and NCX together orchestrate the Ca^{2+} homeostasis of CMs, regulatory proteins such as triadin, junctin and calsequestrin (CSQ), which are coupled to RyRs at the luminal SR⁴⁸, also play a significant role in mediating CICR. For instance, CSQ2 is the most abundant, high-capacity but low-infinity Ca^{2+} -binding protein in the SR. The cardiac isoform can store up to 20 mM Ca^{2+} while buffering the free SR $[\text{Ca}^{2+}]$ at ~ 1 mM⁴⁹, allowing repetitive muscle contractions without run-down. CSQ2 also coordinates the rates of SR Ca^{2+} release and loading by modulating RyR activities, serving as an important determinant of the SR load, which in turn will affect the extents and kinetics of CICR. Our laboratory has demonstrated that forced expression of CSQ, which is otherwise completely absent in hESC-CMs, leads to functional improvements of Ca^{2+} transient parameters as a sign of maturation (Figure 4)⁵⁰. However, CSQ-matured hESC-CMs continued to have immature electrical properties. Genetic suppression of NCX did not lead to a more mature Ca^{2+} -handling phenotype suggesting transgene-specificity (HM Yeung and RA Li, unpublished data).

Electrophysiological properties of hESC/iPSC-CMs

Adult left ventricular (LV) CMs are normally electrically silent-yet-excitabile upon stimulation. The cardiac AP is a result of multiple ion channels and Ca^{2+} -handling proteins interacting in a highly coordinated manner at the single- and multi-cellular levels. Assessing the AP generation and profiles of hESC/iPSC-CMs provide us with valuable information regarding their specific identity and functionality. He et al (2003) were the first to study the electrophysiological properties of hESC-CMs²⁷. They characterized the APs from beating EB outgrowths cultured for 40 to 95 days, with depolarized maximum diastolic potentials (MDP) and slowed APs that are typical of immature embryonic CMs. Unlike the adult counterparts, our own data further showed that the majority of ventricular hESC-CMs fire spontaneously, exhibiting a high degree of automaticity. The remaining quiescent cells could elicit single APs upon stimulation, indicating that their excitability is intact. However, the electrical properties of hESC-CMs are in general immature, akin to arrhythmogenic, failing adult ventricular CMs: prominent “phase 4-like” depolarization, a known substrate for delayed after depolarization (DAD) and significantly depolarized resting membrane potentials (RMPs). Facilitated maturation by various approaches is one of the major objectives of current research. Building upon our series of cardiac automaticity studies^{51–55}, we identified the lack of Kir2.1-encoded I_{K1} in hESC-CMs as the primary mechanistic contributor to the immature pro-arrhythmic electrophysiological properties observed. Forced Kir2.1 expression alone sufficed to render the electrical phenotype indistinguishable from that of primary adult ventricular cells. We are currently developing a non-genetic, non-pharmacologic method for reproducibly driving global maturation, by targeting the microenvironmental niches and other non-cell autonomous means.

Taken collectively, a number of major issues need to be addressed before hESC/iPSC-CMs can be used for clinical applications. In sum, hESC-CMs have immature Ca^{2+} -handling^{38, 46, 50}, with an attenuated transient and heart failure-like U-shaped Ca^{2+} propagation wavefront due to the lack of t-tubule⁴⁷, as well as immature electrical properties with pro-arrhythmic potentials^{51, 56–58}. Their physical size is typically ~ 10 times smaller than adult CMs. Structurally, they lack the ordered organization at the sub-, single- and multi-cellular levels⁵⁹. Furthermore, even with directed cardiac differentiation, the derived populations are always highly heterogeneous by consisting of a mixture of pacemaker, atrial and ventricular derivatives. However, unlike the hematopoietic and neuronal lineages, no convenient cardiac/chamber-specific surface marker have been identified for robust purification³⁵. Recently, a non-genetic method has been developed for sorting pluripotent

stem cell-derived CMs using a dye that labels mitochondria⁶⁰ but atrial and ventricular muscle derivatives still cannot be readily distinguished. Importantly, the long-term safety and functional efficacy of hESC/iPSC-CMs are uncertain, given their reported poor graft survival *in vivo*⁶¹ and our lack of understanding of their immunobiology^{62–65}. Indeed, a recent study shows that iPSCs reprogrammed from autologous somatic cells display significant immunogenicity and can induce T-cell-dependent immune responses in syngeneic recipients, challenging the assumption of patient-specific immunocompatibility⁶⁶. Whether the same applies to iPSC-CMs remains unknown. Despite these hurdles, with a better understanding of the basic biology of hESC/iPSC-CMs, as outlined in the select examples given above for Ca²⁺-handling and electrophysiology, there is every reason to believe that more significant and robust advances can be achieved in the foreseeable future.

Tissue Engineering – Physical Alignment of hESC-CMs and Engineered Cardiac Tissue Constructs

The ventricular myocardium is a highly complex structure consisting of aligned, connected CMs, stromal cells and a vascular network systematically embedded in a mesh of extracellular matrix. Although the successful development of directed cardiac differentiation has made possible the derivation of hESC-CMs with high yields, hESC-CMs differentiated *in vitro* lack the sub-cellular organization and higher order structural 2- or 3-dimensionality seen in adult heart. Therefore, there is a need to apply tissue engineering techniques to put hESC-CMs together to better mimic the native heart tissues for better safety and efficacy. Indeed, when grown on a micro-grooved culture platform, hESC-CMs align and display the typical banding pattern consistent with organized sarcomeric structure patterns⁵⁹ (Figure 5) that is never seen in controls. Quantitative assessment based on nuclei shape and actin organization show that the hESC-CMs exhibit increased alignment on the microgrooved substrates. Functionally, high-resolution optical mapping reveals that aligned monolayers of hESC-VCMs display anisotropic conduction properties with distinct longitudinal and transverse velocities, a signature characteristic of the native heart, not seen in control randomly organized monolayers (Lieu, Wang, Khine and Li, unpublished data). This finding resembles those previously reported for neonatal rat ventricular cardiomyocytes⁶⁷. Three-dimensionally, the Costa lab constructs engineered cardiac tissue constructs (ECTs) including cardiac papillary-like muscle strips as well as ventricle-like “organoid” chambers that exhibit key characteristics of cardiac physiology by ejecting fluid and displaying force-frequency and pressure-volume relationships^{68–69}. Various similar tissue engineering approaches have been independently developed and employed by several other labs^{70–74}. Although these techniques were often first developed using neonatal rodent ventricular cells, they are now being applied to hESC/iPSC-CMs with improved cell yields from directed cardiac differentiation. Not only will further optimization of hESC/iPSC-based ECTs provide powerful tools for disease modeling, drug/cardiotoxicity screening and clinical translations, but the physiologic 3D environment constructed also promises to reveal novel insights not possible with conventional rigid 2D culture systems.

MicroRNA- and Pluripotent Stem Cell-based Heart Therapies

MicroRNAs (miRs) are non-encoding RNAs of ~22 nucleotides that function as negative transcriptional regulators via degradation or inhibition by RNA interference^{75–76}. They have been suggested to regulate ~30% of human genes⁷⁷. To date, 706 human miRs have been identified, of which approximately 50% of pre-miR sequences are located within introns according to the Sanger Database. The expression of miRs is highly regulated and dependent on tissue, cell type, metabolic status and diseases states. Recent studies have demonstrated that miRs are important regulators of cardiovascular cell differentiation, growth, proliferation and apoptosis. In the heart, some of the most abundant miRs include miR-1,

let-7, miR-133, miR-126-3p, miR-30c, and miR-26a⁷⁸. In particular, miR-1, miR-133⁷⁹ and miR-208 are specific to cardiac and skeletal muscles. Various recent profiling efforts have revealed profound alterations of miR expression in the pathogenesis of human heart failure^{80–82}. Abnormal miR expression patterns have also been detected in hypertrophy and arrhythmias.

There have been few studies on the role of miR in hESC/iPSC-CMs. Ivey et al showed that miR-1 promotes differentiation of mouse and human ESCs into the cardiac lineage, as evidenced by an increased expression of nkx2.5 and percentage of spontaneously contracting EB outgrowths⁸³. Our group recently mapped and compared the miR profiles of hESC, hESC-derived VCMs (hESC-VCM), human fetal and adult VCMs⁸⁴. Sixty-three miRNAs were differentially expressed in hESC-VCMs compared to hESCs, of which 23 were also expressed highly in human fetal and adult VCMs. miR-1 and miR-499 displayed the highest degree of differential expression and thus were chosen for further characterization. Overexpression of miR-499 by lentiviral transduction significantly enhanced the differentiation of cardiac progenitors into VCMs. By contrast, miR-1 overexpression did not affect the yield of VCMs from hESC differentiation, but decreased action potential duration (APD) and hyperpolarized resting membrane potential (RMP)/maximum diastolic potential (MDP) in hESC-VCM due to increased I_{to} , I_{Ks} and I_{Kr} , and decreased I_f as signs of maturation (unpublished). Taken collectively, miR-499 seems to promote ventricular specification of hESCs, while miR-1 serves to facilitate electrophysiological maturation.

Human ESC-based Bio-artificial SAN (Bio-SAN) as an alternative to Electronic Pacemakers

Normal rhythms originate in the SAN, whose malfunction leads to rhythm generation disorders. While conventional treatments of pharmacological intervention and/or implantation of electronic pacemakers are effective, they are associated with shortcomings such as potential infection, finite battery life, permanent implantation of leads, and the lack of intrinsic responsiveness to neurohumoral regulation. Various cell- and gene-based approaches have been developed by us^{28, 51, 55, 85} and others^{86–87} to reconstruct a functional bioartificial SAN (bio-SAN) as an alternative or supplement to electronic devices. By genetically overexpressing a genuine pacemaker gene product, the hyperpolarization-activated cyclic nucleotide-modulated (HCN) channels, we confer upon normally-quiescent cardiac muscle cells the ability to intrinsically fire APs similar to genuine nodal pacemaker cells^{28, 51, 55}. Importantly, when this HCN gene-based bio-SAN is tested in a large animal (swine) model of sick sinus syndrome (SSS)⁸⁵, side-by-side comparison shows that bio-SAN significantly reduces the dependence on device-supported pacing by electronic pacemaker from ~85% to ~15% in the same animal after receiving our treatment. Alternatively, pluripotent human embryonic stem cells (hESCs) can be differentiated into electrically-active cardiac derivatives that mimic pacemaker cells for transplantation to construct an *in vivo* bio-SAN^{28, 87}. Unlike myocardial repair, cell-based bio-SAN requires relatively much fewer cells (several thousands versus tens or hundreds of millions or more). Furthermore, a simple injection of cells (or gene delivery vehicle) suffices to induce a local ectopic pacing site. As such, a functional bio-SAN, with its structure as a node or sphere of cells, is comparatively less complex than the thick left ventricular wall. We are currently exploring the possibility of using nodal progenitors. We are also testing the long-term safety and efficacy of bio-SAN and non-invasive catheter-based delivery techniques for implantation. The use of iPSC as bio-SAN has not been explored.

Myocardial transplantation

Myocardial infarction (MI), generally known as heart attack, results from the blockage of blood supply to the myocardial tissues leading to cardiac cell death. Delayed thrombolytic treatment of the blocked coronary artery leads to irreversible and permanent impairment of the heart. Sudden cardiac death (SCD) due to ventricular arrhythmias following MI-induced impairment remains a leading cause of morbidity and mortality in the industrialized world. Even a patient survives an attack, the remaining CMs hypertrophy in an attempt to meet the functional demands, while cardiac fibroblasts secrete collagen and other extracellular matrix proteins during scar formation, which may further impair ventricular function. Since terminally differentiated myocardial tissue possesses limited regenerative capacity, clinical treatments remain palliative. Pluripotent stem cells have led to the development of various cell-based therapies that have shown significant promises in at least partially restoring cardiac function⁹. However, as already described, hESC- and iPSC-CMs display a range of functional and structural properties that are remarkably similar to those of immature or failing heart cells. Generation of functionally mature myocytes which can activate complex signaling processes that reverse remodel the failing heart and prevent the incidence of arrhythmias is an area of active investigations. Transplantation of hESC-CMs intramyocardially into immunocompromised (NOD-SCID) mice with myocardial infarction (MI) resulted in rapid formation of grafts with significant improvement in cardiac function at 1 month⁸⁸, similar to those observed for rats with MI³⁰. However, this beneficial effect does not sustain after 12 weeks despite graft survival and irrespective of its size⁸⁹, suggesting that the long-term efficacy of cardiac cell transplantation is uncertain. Indeed, the same beneficial effect of hESC-CMs transplantation observed in acute MI models is not seen in chronic MI models⁹⁰. Better delivery protocols and engineered constructs may be needed to overcome these hurdles.

Summary

The availability of hESC and iPSC and their successful differentiation into genuine human heart cells have enabled clinicians and scientists to gain insights into the early development of the human heart as well as to pursue to the revolutionary paradigm of heart regeneration. However, hESC- and iPSC-derived CMs appear to be both structurally and functionally immature. One of the most important factors to consider before any potential benefits of hESC-CMs are clinically assessed would be to ensure their safety. Furthermore, the successful use of derived CMs as human heart disease models and cardiotoxicity screening tools depends on their ability to recapitulate the properties of their adult counterparts. Further studies are required to promote their maturation. When combined with other advances in driven differentiation and cardiovascular progenitor identification^{34, 91–92}, the approaches can facilitate the translation of hESC/iPSCs into clinical and other applications.

Acknowledgments

This work was supported by grants from the NIH - R01 HL72857 (to R.A.L.), Research Grant Council (to R.A.L.), the CC Wong Foundation Stem Cell Fund (to R.A.L.) and the HKU Development Fund (to E.P., C.W.K. and R.A.L.).

References

1. Murry CE, Soonpaa MH, Reinecke H, Nakajima H, Nakajima HO, Rubart M, Pasumarthi KB, Virag JJ, Bartelmez SH, Poppa V, Bradford G, Dowell JD, Williams DA, Field LJ. Haematopoietic stem cells do not transdifferentiate into cardiac myocytes in myocardial infarcts. *Nature*. 2004; 428(6983):664–668. [PubMed: 15034593]

2. Balsam LB, Wagers AJ, Christensen JL, Kofidis T, Weissman IL, Robbins RC. Haematopoietic stem cells adopt mature haematopoietic fates in ischaemic myocardium. *Nature*. 2004; 428(6983): 668–673. [PubMed: 15034594]
3. Menasche P, Hagege AA, Vilquin JT, Desnos M, Abergel E, Pouzet B, Bel A, Sarateanu S, Scorsin M, Schwartz K, Bruneval P, Benbunan M, Marolleau JP, Duboc D. Autologous skeletal myoblast transplantation for severe postinfarction left ventricular dysfunction. *J Am Coll Cardiol*. 2003; 41(7):1078–1083. [PubMed: 12679204]
4. Smits PC, van Geuns RJ, Poldermans D, Bountiokos M, Onderwater EE, Lee CH, Maat AP, Serruys PW. Catheter-based intramyocardial injection of autologous skeletal myoblasts as a primary treatment of ischemic heart failure: clinical experience with six-month follow-up. *J Am Coll Cardiol*. 2003; 42(12):2063–2069. [PubMed: 14680727]
5. Thomson JA, Itskovitz-Eldor J, Shapiro SS, Waknitz MA, Swiergiel JJ, Marshall VS, Jones JM. Embryonic stem cell lines derived from human blastocysts. *Science*. 1998; 282(5391):1145–1147. [PubMed: 9804556]
6. Kehat I, Kenyagin-Karsenti D, Snir M, Segev H, Amit M, Gepstein A, Livne E, Binah O, Itskovitz-Eldor J, Gepstein L. Human embryonic stem cells can differentiate into myocytes with structural and functional properties of cardiomyocytes. *J Clin Invest*. 2001; 108(3):407–414. [PubMed: 11489934]
7. Xu C, Police S, Rao N, Carpenter MK. Characterization and enrichment of cardiomyocytes derived from human embryonic stem cells. *Circ Res*. 2002; 91(6):501–508. [PubMed: 12242268]
8. Laflamme MA, Chen KY, Naumova AV, Muskheli V, Fugate JA, Dupras SK, Reinecke H, Xu C, Hassanipour M, Police S, O'Sullivan C, Collins L, Chen Y, Minami E, Gill EA, Ueno S, Yuan C, Gold J, Murry CE. Cardiomyocytes derived from human embryonic stem cells in pro-survival factors enhance function of infarcted rat hearts. *Nat Biotechnol*. 2007; 25(9):1015–1024. [PubMed: 17721512]
9. Caspi O, Huber I, Kehat I, Habib M, Arbel G, Gepstein A, Yankelson L, Aronson D, Beyar R, Gepstein L. Transplantation of human embryonic stem cell-derived cardiomyocytes improves myocardial performance in infarcted rat hearts. *J Am Coll Cardiol*. 2007; 50(19):1884–1893. [PubMed: 17980256]
10. Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K, Yamanaka S. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. *Cell*. 2007; 131(5):861–872. [PubMed: 18035408]
11. Yu J, Vodyanik MA, Smuga-Otto K, Antosiewicz-Bourget J, Frane JL, Tian S, Nie J, Jonsdottir GA, Ruotti V, Stewart R, Slukvin II, Thomson JA. Induced pluripotent stem cell lines derived from human somatic cells. *Science*. 2007; 318(5858):1917–1920. [PubMed: 18029452]
12. Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. *Cell*. 2006; 126(4):663–676. [PubMed: 16904174]
13. Huangfu D, Osafune K, Maehr R, Guo W, Eijkelenboom A, Chen S, Muhlestein W, Melton DA. Induction of pluripotent stem cells from primary human fibroblasts with only Oct4 and Sox2. *Nat Biotechnol*. 2008; 26(11):1269–1275. [PubMed: 18849973]
14. Nakagawa M, Koyanagi M, Tanabe K, Takahashi K, Ichisaka T, Aoi T, Okita K, Mochiduki Y, Takizawa N, Yamanaka S. Generation of induced pluripotent stem cells without Myc from mouse and human fibroblasts. *Nat Biotechnol*. 2008; 26(1):101–106. [PubMed: 18059259]
15. Kim JB, Zaehres H, Wu G, Gentile L, Ko K, Sebastiano V, Arauzo-Bravo MJ, Ruau D, Han DW, Zenke M, Scholer HR. Pluripotent stem cells induced from adult neural stem cells by reprogramming with two factors. *Nature*. 2008
16. Warren L, Manos PD, Ahfeldt T, Loh YH, Li H, Lau F, Ebina W, Mandal PK, Smith ZD, Meissner A, Daley GQ, Brack AS, Collins JJ, Cowan C, Schlaeger TM, Rossi DJ. Highly efficient reprogramming to pluripotency and directed differentiation of human cells with synthetic modified mRNA. *Cell Stem Cell*. 2010; 7(5):618–630. [PubMed: 20888316]
17. Gore A, Li Z, Fung HL, Young JE, Agarwal S, Antosiewicz-Bourget J, Canto I, Giorgetti A, Israel MA, Kiskinis E, Lee JH, Loh YH, Manos PD, Montserrat N, Panopoulos AD, Ruiz S, Wilbert ML, Yu J, Kirkness EF, Izpisua Belmonte JC, Rossi DJ, Thomson JA, Eggan K, Daley GQ, Goldstein LS, Zhang K. Somatic coding mutations in human induced pluripotent stem cells. *Nature*. 2011; 471(7336):63–67. [PubMed: 21368825]

18. Zhang J, Wilson GF, Soerens AG, Koonce CH, Yu J, Palecek SP, Thomson JA, Kamp TJ. Functional cardiomyocytes derived from human induced pluripotent stem cells. *Circ Res.* 2009; 104(4):e30–e41. [PubMed: 19213953]
19. Efe JA, Hilcove S, Kim J, Zhou H, Ouyang K, Wang G, Chen J, Ding S. Conversion of mouse fibroblasts into cardiomyocytes using a direct reprogramming strategy. *Nat Cell Biol.* 2011; 13(3): 215–222. [PubMed: 21278734]
20. Xu H, Yi BA, Chien KR. Shortcuts to making cardiomyocytes. *Nat Cell Biol.* 2011; 13(3):191–193. [PubMed: 21364566]
21. Abu-Issa R, Kirby ML. Heart field: from mesoderm to heart tube. *Annu Rev Cell Dev Biol.* 2007; 23:45–68. [PubMed: 17456019]
22. Buckingham M, Meilhac S, Zaffran S. Building the mammalian heart from two sources of myocardial cells. *Nat Rev Genet.* 2005; 6(11):826–835. [PubMed: 16304598]
23. Garry DJ, Olson EN. A common progenitor at the heart of development. *Cell.* 2006; 127(6):1101–1104. [PubMed: 17174889]
24. Ahuja P, Sdek P, MacLellan WR. Cardiac myocyte cell cycle control in development, disease, and regeneration. *Physiol Rev.* 2007; 87(2):521–544. [PubMed: 17429040]
25. McGill CJ, Brooks G. Cell cycle control mechanisms and their role in cardiac growth. *Cardiovasc Res.* 1995; 30(4):557–569. [PubMed: 8575004]
26. Boheler KR, Czyz J, Tweedie D, Yang HT, Anisimov SV, Wobus AM. Differentiation of pluripotent embryonic stem cells into cardiomyocytes. *Circ Res.* 2002; 91(3):189–201. [PubMed: 12169644]
27. He JQ, Ma Y, Lee Y, Thomson JA, Kamp TJ. Human embryonic stem cells develop into multiple types of cardiac myocytes: action potential characterization. *Circ Res.* 2003; 93(1):32–39. [PubMed: 12791707]
28. Xue T, Cho HC, Akar FG, Tsang SY, Jones SP, Marban E, Tomaselli GF, Li RA. Functional integration of electrically active cardiac derivatives from genetically engineered human embryonic stem cells with quiescent recipient ventricular cardiomyocytes: insights into the development of cell-based pacemakers. *Circulation.* 2005; 111(1):11–20. [PubMed: 15611367]
29. Mummery C, Ward-van Oostwaard D, Doevendans P, Spijker R, van den Brink S, Hassink R, van der Heyden M, Opthof T, Pera M, de la Riviere AB, Passier R, Tertoolen L. Differentiation of human embryonic stem cells to cardiomyocytes: role of coculture with visceral endoderm-like cells. *Circulation.* 2003; 107(21):2733–2740. [PubMed: 12742992]
30. Laflamme MA, Chen KY, Naumova AV, Muskheli V, Fugate JA, Dupras SK, Reinecke H, Xu C, Hassanipour M, Police S, O'Sullivan C, Collins L, Chen Y, Minami E, Gill EA, Ueno S, Yuan C, Gold J, Murry CE. Cardiomyocytes derived from human embryonic stem cells in pro-survival factors enhance function of infarcted rat hearts. *Nat Biotechnol.* 2007; 25(9):1015–1024. [PubMed: 17721512]
31. Zhu WZ, Xie Y, Moyes KW, Gold JD, Askari B, Laflamme MA. Neuregulin/ErbB signaling regulates cardiac subtype specification in differentiating human embryonic stem cells. *Circ Res.* 2010; 107(6):776–786. [PubMed: 20671236]
32. Passier R, Oostwaard DW, Snapper J, Kloots J, Hassink RJ, Kuijk E, Roelen B, de la Riviere AB, Mummery C. Increased cardiomyocyte differentiation from human embryonic stem cells in serum-free cultures. *Stem Cells.* 2005; 23(6):772–780. [PubMed: 15917473]
33. Xu XQ, Graichen R, Soo SY, Balakrishnan T, Rahmat SN, Sieh S, Tham SC, Freund C, Moore J, Mummery C, Colman A, Zweigerdt R, Davidson BP. Chemically defined medium supporting cardiomyocyte differentiation of human embryonic stem cells. *Differentiation.* 2008; 76(9):958–970. [PubMed: 18557764]
34. Yang L, Soonpaa MH, Adler ED, Roepke TK, Kattman SJ, Kennedy M, Henckaerts E, Bonham K, Abbott GW, Linden RM, Field LJ, Keller GM. Human cardiovascular progenitor cells develop from a KDR+ embryonic-stem-cell-derived population. *Nature.* 2008; 453(7194):524–528. [PubMed: 18432194]
35. Chan JW, Lieu DK, Huser T, Li RA. Label-free separation of human embryonic stem cells and their cardiac derivatives using Raman spectroscopy. *Anal Chem.* 2009; 81(4):1324–1331. [PubMed: 19152312]

36. Anderson D, Self T, Mellor IR, Goh G, Hill SJ, Denning C. Transgenic enrichment of cardiomyocytes from human embryonic stem cells. *Mol Ther.* 2007; 15(11):2027–2036. [PubMed: 17895862]
37. Huber I, Itzhaki I, Caspi O, Arbel G, Tzukerman M, Gepstein A, Habib M, Yankelson L, Kehat I, Gepstein L. Identification and selection of cardiomyocytes during human embryonic stem cell differentiation. *FASEB J.* 2007; 21(10):2551–2563. [PubMed: 17435178]
38. Fu JD, Jiang P, Rushing S, Liu J, Chiamvimonvat N, Li RA. Na⁺/Ca²⁺ exchanger is a determinant of excitation-contraction coupling in human embryonic stem cell-derived ventricular cardiomyocytes. *Stem Cells Dev.* 2010
39. Bers DM. Cardiac excitation-contraction coupling. *Nature.* 2002; 415(6868):198–205. [PubMed: 11805843]
40. Brette F, Orchard C. T-tubule function in mammalian cardiac myocytes. *Circ Res.* 2003; 92(11):1182–1192. [PubMed: 12805236]
41. Brette F, Orchard C. Resurgence of cardiac t-tubule research. *Physiology (Bethesda).* 2007; 22:167–173. [PubMed: 17557937]
42. Song LS, Guatimosim S, Gomez-Viquez L, Sobie EA, Ziman A, Hartmann H, Lederer WJ. Calcium biology of the transverse tubules in heart. *Ann N Y Acad Sci.* 2005; 1047:99–111. [PubMed: 16093488]
43. Moore JC, Fu J, Chan YC, Lin D, Tran H, Tse HF, Li RA. Distinct cardiogenic preferences of two human embryonic stem cell (hESC) lines are imprinted in their proteomes in the pluripotent state. *Biochem Biophys Res Commun.* 2008; 372(4):553–558. [PubMed: 18503758]
44. Zwi L, Caspi O, Arbel G, Huber I, Gepstein A, Park IH, Gepstein L. Cardiomyocyte differentiation of human induced pluripotent stem cells. *Circulation.* 2009; 120(15):1513–1523. [PubMed: 19786631]
45. Dolnikov K, Shilkut M, Zeevi-Levin N, Gerecht-Nir S, Amit M, Danon A, Itskovitz-Eldor J, Binah O. Functional properties of human embryonic stem cell-derived cardiomyocytes: intracellular Ca²⁺ handling and the role of sarcoplasmic reticulum in the contraction. *Stem Cells.* 2006; 24(2):236–245. [PubMed: 16322641]
46. Liu J, Fu JD, Siu CW, Li RA. Functional sarcoplasmic reticulum for calcium handling of human embryonic stem cell-derived cardiomyocytes: insights for driven maturation. *Stem Cells.* 2007; 25(12):3038–3044. [PubMed: 17872499]
47. Lieu DK, Liu J, Siu CW, McNerney GP, Tse HF, Abu-Khalil A, Huser T, Li RA. Absence of transverse tubules contributes to non-uniform Ca(2+) wavefronts in mouse and human embryonic stem cell-derived cardiomyocytes. *Stem Cells Dev.* 2009; 18(10):1493–1500. [PubMed: 19290776]
48. Zhang L, Kelley J, Schmeisser G, Kobayashi YM, Jones LR. Complex formation between junctin, triadin, calsequestrin, and the ryanodine receptor. Proteins of the cardiac junctional sarcoplasmic reticulum membrane. *J Biol Chem.* 1997; 272(37):23389–23397. [PubMed: 9287354]
49. Beard NA, Laver DR, Dulhunty AF. Calsequestrin and the calcium release channel of skeletal and cardiac muscle. *Prog Biophys Mol Biol.* 2004; 85(1):33–69. [PubMed: 15050380]
50. Liu J, Lieu DK, Siu CW, Fu JD, Tse HF, Li RA. Facilitated maturation of Ca²⁺ handling properties of human embryonic stem cell-derived cardiomyocytes by calsequestrin expression. *Am J Physiol Cell Physiol.* 2009; 297(1):C152–C159. [PubMed: 19357236]
51. Lieu DK, Chan YC, Lau CP, Tse HF, Siu CW, Li RA. Overexpression of HCN-encoded pacemaker current silences bioartificial pacemakers. *Heart Rhythm.* 2008; 5(9):1310–1317. [PubMed: 18693074]
52. Azene EM, Xue T, Marban E, Tomaselli GF, Li RA. Non-equilibrium behavior of HCN channels: insights into the role of HCN channels in native and engineered pacemakers. *Cardiovasc Res.* 2005; 67(2):263–273. [PubMed: 16005302]
53. Chan YC, Siu CW, Lau YM, Lau CP, Li RA, Tse HF. Synergistic effects of inward rectifier (I) and pacemaker (I) currents on the induction of bioengineered cardiac automaticity. *J Cardiovasc Electrophysiol.* 2009; 20(9):1048–1054. [PubMed: 19460073]
54. Siu CW, Lieu DK, Li RA. HCN-encoded pacemaker channels: from physiology and biophysics to bioengineering. *J Membr Biol.* 2006; 214(3):115–122. [PubMed: 17558529]

55. Xue T, Siu CW, Lieu DK, Lau CP, Tse HF, Li RA. Mechanistic role of I(f) revealed by induction of ventricular automaticity by somatic gene transfer of gating-engineered pacemaker (HCN) channels. *Circulation*. 2007; 115(14):1839–1850. [PubMed: 17389267]
56. Moore JC, van Laake LW, Braam SR, Xue T, Tsang SY, Ward D, Passier R, Tertoolen LL, Li RA, Mummery CL. Human embryonic stem cells: genetic manipulation on the way to cardiac cell therapies. *Reprod Toxicol*. 2005; 20(3):377–391. [PubMed: 15967632]
57. Cao F, Wagner RA, Wilson KD, Xie X, Fu JD, Drukker M, Lee A, Li RA, Gambhir SS, Weissman IL, Robbins RC, Wu JC. Transcriptional and functional profiling of human embryonic stem cell-derived cardiomyocytes. *PLoS ONE*. 2008; 3(10):e3474. [PubMed: 18941512]
58. Dudley SC Jr, Hoch NE, McCann LA, Honeycutt C, Diamandopoulos L, Fukai T, Harrison DG, Dikalov SI, Langberg J. Atrial fibrillation increases production of superoxide by the left atrium and left atrial appendage: role of the NADPH and xanthine oxidases. *Circulation*. 2005; 112(9):1266–1273. [PubMed: 16129811]
59. Luna JJ, Ciriza J, Garcia-Ojeda ME, Kong M, Herren A, Lieu DK, Li RA, Fowlkes CC, Khine M, McCloskey KE. Multiscale biomimetic topography for the alignment of neonatal and embryonic stem cell-derived heart cells. *Tissue Eng Part C Methods*. 2011; 17(5):579–588. [PubMed: 21235325]
60. Hattori F, Chen H, Yamashita H, Tohyama S, Satoh YS, Yuasa S, Li W, Yamakawa H, Tanaka T, Onitsuka T, Shimoji K, Ohno Y, Egashira T, Kaneda R, Murata M, Hidaka K, Morisaki T, Sasaki E, Suzuki T, Sano M, Makino S, Oikawa S, Fukuda K. Nongenetic method for purifying stem cell-derived cardiomyocytes. *Nat Methods*. 2010; 7(1):61–66. [PubMed: 19946277]
61. Cao F, Lin S, Xie X, Ray P, Patel M, Zhang X, Drukker M, Dylla SJ, Connolly AJ, Chen X, Weissman IL, Gambhir SS, Wu JC. In vivo visualization of embryonic stem cell survival, proliferation, and migration after cardiac delivery. *Circulation*. 2006; 113(7):1005–1014. [PubMed: 16476845]
62. Abdullah Z, Saric T, Kashkar H, Baschuk N, Yazdanpanah B, Fleischmann BK, Hescheler J, Kronke M, Utermohlen O. Serpin-6 expression protects embryonic stem cells from lysis by antigen-specific CTL. *J Immunol*. 2007; 178(6):3390–3399. [PubMed: 17339433]
63. Swijnenburg RJ, Tanaka M, Vogel H, Baker J, Kofidis T, Gunawan F, Lebl DR, Caffarelli AD, de Bruin JL, Fedoseyeva EV, Robbins RC. Embryonic stem cell immunogenicity increases upon differentiation after transplantation into ischemic myocardium. *Circulation*. 2005; 112(9 Suppl):I166–I172. [PubMed: 16159810]
64. Kadereit S, Trounson A. In vitro immunogenicity of undifferentiated pluripotent stem cells (PSC) and derived lineages. *Semin Immunopathol*. 2011
65. de Rham C, Villard J. How to cross immunogenetic hurdles to human embryonic stem cell transplantation. *Semin Immunopathol*. 2011
66. Zhao T, Zhang Z-N, Rong Z, Xu Y. Immunogenicity of induced pluripotent stem cells. *Nature*. 2011; 474(7350):212–215. [PubMed: 21572395]
67. Bursac N, Parker KK, Irvanian S, Tung L. Cardiomyocyte cultures with controlled macroscopic anisotropy: a model for functional electrophysiological studies of cardiac muscle. *Circ Res*. 2002; 91(12):e45–e54. [PubMed: 12480825]
68. Lee EJ, Kim do E, Azeloglu EU, Costa KD. Engineered cardiac organoid chambers: toward a functional biological model ventricle. *Tissue Eng Part A*. 2008; 14(2):215–225. [PubMed: 18333774]
69. Kim do E, Lee EJ, Martens TP, Kara R, Chaudhry HW, Itescu S, Costa KD. Engineered cardiac tissues for in vitro assessment of contractile function and repair mechanisms. *Conf Proc IEEE Eng Med Biol Soc*. 2006; 1:849–852. [PubMed: 17946863]
70. Tulloch NL, Muskheili V, Razumova MV, Korte FS, Regnier M, Hauch KD, Pabon L, Reinecke H, Murry CE. Growth of engineered human myocardium with mechanical loading and vascular coculture. *Circ Res*. 2011; 109(1):47–59. [PubMed: 21597009]
71. Zimmermann WH, Didie M, Doker S, Melnychenko I, Naito H, Rogge C, Tiburcy M, Eschenhagen T. Heart muscle engineering: an update on cardiac muscle replacement therapy. *Cardiovasc Res*. 2006; 71(3):419–429. [PubMed: 16697358]

72. Eschenhagen T, Zimmermann WH. Engineering myocardial tissue. *Circ Res*. 2005; 97(12):1220–1231. [PubMed: 16339494]
73. Chien KR, Domian IJ, Parker KK. Cardiogenesis and the complex biology of regenerative cardiovascular medicine. *Science*. 2008; 322(5907):1494–1497. [PubMed: 19056974]
74. Vunjak-Novakovic G, Tandon N, Godier A, Maidhof R, Marsano A, Martens TP, Radisic M. Challenges in cardiac tissue engineering. *Tissue Eng Part B Rev*. 2010; 16(2):169–187. [PubMed: 19698068]
75. Ambros V. The functions of animal microRNAs. *Nature*. 2004; 431(7006):350–355. [PubMed: 15372042]
76. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. *Cell*. 2004; 116(2):281–297. [PubMed: 14744438]
77. Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. *Cell*. 2005; 120(1):15–20. [PubMed: 15652477]
78. Lagos-Quintana M, Rauhut R, Yalcin A, Meyer J, Lendeckel W, Tuschl T. Identification of tissue-specific microRNAs from mouse. *Curr Biol*. 2002; 12(9):735–739. [PubMed: 12007417]
79. Care A, Catalucci D, Felicetti F, Bonci D, Addario A, Gallo P, Bang ML, Segnalini P, Gu Y, Dalton ND, Elia L, Latronico MV, Hoydal M, Autore C, Russo MA, Dorn GW 2nd, Ellingsen O, Ruiz-Lozano P, Peterson KL, Croce CM, Peschle C, Condorelli G. MicroRNA-133 controls cardiac hypertrophy. *Nat Med*. 2007; 13(5):613–618. [PubMed: 17468766]
80. Cheng Y, Ji R, Yue J, Yang J, Liu X, Chen H, Dean DB, Zhang C. MicroRNAs are aberrantly expressed in hypertrophic heart: do they play a role in cardiac hypertrophy? *Am J Pathol*. 2007; 170(6):1831–1840. [PubMed: 17525252]
81. Matkovich SJ, Van Booven DJ, Youker KA, Torre-Amione G, Diwan A, Eschenbacher WH, Dorn LE, Watson MA, Margulies KB, Dorn GW 2nd. Reciprocal regulation of myocardial microRNAs and messenger RNA in human cardiomyopathy and reversal of the microRNA signature by biomechanical support. *Circulation*. 2009; 119(9):1263–1271. [PubMed: 19237659]
82. Thum T, Galuppo P, Wolf C, Fiedler J, Kneitz S, van Laake LW, Doevendans PA, Mummery CL, Borlak J, Haverich A, Gross C, Engelhardt S, Ertl G, Bauersachs J. MicroRNAs in the human heart: a clue to fetal gene reprogramming in heart failure. *Circulation*. 2007; 116(3):258–267. [PubMed: 17606841]
83. Ivey KN, Muth A, Arnold J, King FW, Yeh RF, Fish JE, Hsiao EC, Schwartz RJ, Conklin BR, Bernstein HS, Srivastava D. MicroRNA regulation of cell lineages in mouse and human embryonic stem cells. *Cell Stem Cell*. 2008; 2(3):219–229. [PubMed: 18371447]
84. Wilson KD, Hu S, Venkatasubrahmanyam S, Fu JD, Sun N, Abilez OJ, Baugh JJ, Jia F, Ghosh Z, Li RA, Butte AJ, Wu JC. Dynamic microRNA expression programs during cardiac differentiation of human embryonic stem cells: role for miR-499. *Circ Cardiovasc Genet*. 2010; 3(5):426–435. [PubMed: 20733065]
85. Tse HF, Xue T, Lau CP, Siu CW, Wang K, Zhang QY, Tomaselli GF, Akar FG, Li RA. Bioartificial sinus node constructed via in vivo gene transfer of an engineered pacemaker HCN Channel reduces the dependence on electronic pacemaker in a sick-sinus syndrome model. *Circulation*. 2006; 114(10):1000–1011. [PubMed: 16923751]
86. Robinson RB, Brink PR, Cohen IS, Rosen MR. I(f) and the biological pacemaker. *Pharmacol Res*. 2006; 53(5):407–415. [PubMed: 16621592]
87. Kehat I, Khimovich L, Caspi O, Gepstein A, Shofti R, Arbel G, Huber I, Satin J, Itskovitz-Eldor J, Gepstein L. Electromechanical integration of cardiomyocytes derived from human embryonic stem cells. *Nat Biotechnol*. 2004; 22(10):1282–1289. [PubMed: 15448703]
88. van Laake LW, Passier R, Monshouwer-Kloots J, Verkleij AJ, Lips DJ, Freund C, den Ouden K, Ward-van Oostwaard D, Korving J, Tertoolen LG, van Echteld CJ, Doevendans PA, Mummery CL. Human embryonic stem cell-derived cardiomyocytes survive and mature in the mouse heart and transiently improve function after myocardial infarction. *Stem Cell Res*. 2007; 1(1):9–24. [PubMed: 19383383]

89. van Laake LW, Passier R, Doevendans PA, Mummery CL. Human embryonic stem cell-derived cardiomyocytes and cardiac repair in rodents. *Circ Res.* 2008; 102(9):1008–1010. [PubMed: 18436793]
90. Fernandes S, Naumova AV, Zhu WZ, Laflamme MA, Gold J, Murry CE. Human embryonic stem cell-derived cardiomyocytes engraft but do not alter cardiac remodeling after chronic infarction in rats. *J Mol Cell Cardiol.* 2010; 49(6):941–949. [PubMed: 20854826]
91. Bu L, Jiang X, Martin-Puig S, Caron L, Zhu S, Shao Y, Roberts DJ, Huang PL, Domian IJ, Chien KR. Human ISL1 heart progenitors generate diverse multipotent cardiovascular cell lineages. *Nature.* 2009; 460(7251):113–117. [PubMed: 19571884]
92. Moretti A, Caron L, Nakano A, Lam JT, Bernshausen A, Chen Y, Qyang Y, Bu L, Sasaki M, Martin-Puig S, Sun Y, Evans SM, Laugwitz KL, Chien KR. Multipotent embryonic isl1+ progenitor cells lead to cardiac, smooth muscle, and endothelial cell diversification. *Cell.* 2006; 127(6):1151–1165. [PubMed: 17123592]

Figure 1.

A, C) Action potentials and B, D) pie graphs showing the % distribution of chamber-specific CMs from HES2 and H1, respectively. Adopted from Moore et al 2008.

Figure 2.

A) Representative tracings caffeine-induced Ca^{2+} transients of HES2-, H1-, and FLV-CMs. **B)** % of caffeine-responsive and -insensitive cells. **C)** Expression of various Ca^{2+} handling proteins. β -actin was used as the loading control. **D)** Immunostaining of RyRs. Adopted from Liu et al 2007.

Figure 3.

T-tubule imaging of a hESC-CM and a mature ventricular CM. Di-8-ANEPPS confocal microscopic images of a hESC-CM (**A**) did not show intracellular fluorescent spots like those in an adult guinea pig ventricular CM (**C**) suggesting the absence of t-tubules. The absence of t-tubules in ESC-CMs was further confirmed by atomic force microscopy (AFM) imaging of an adult ventricular cardiomyocyte (**D**) showing regularly spaced pores in the sarcolemma that coincide with the Z-lines, while hESC-CM (**B**) surface showed comparatively smoother topology with no presence of invaginations that are indicative of t-tubules. **E**) Electrically induced Ca^{2+} transient in hESC-CMs. *Top*: Time progression line scans of pseudo-colored transient increase in intracellular Ca^{2+} across the mid-plane of a hESC-CM showed a U-shaped wavefront. *Bottom*: Quantified Ca^{2+} transient of line scans of the top panel. Adopted from Lieu et al 2009.

Figure 4. Effect of CSQ overexpression on hESC-CMs. **A)** Representative electrically-induced Ca²⁺ transient tracings for Ad-GFP (n=12) and Ad-CSQ (n=29) transduced hESC-CMs. **B)** Bar graphs of amplitude. * P < 0.05, ** P < 0.01 Adopted from Liu et al 2009.

Figure 5. Confocal micrographs of hESC-derived CMs alignment on wrinkles. HESC-CMs were isolated and cultured on flat substrate (**A**) and wrinkle substrates (**B**) for 8 days. Green indicates tropomyosin staining, blue nuclear staining DAPI. **C**) Image processing was used to detect the orientation of the DAPI-labeled nuclei. **D**) Anisotropy analysis of control (black) versus red (on wrinkles) showing that 90° is direction of wrinkles. The thinner lines indicate the standard deviations. Adopted from Luna et al 2010.

Table 1**Table summary of differences**

H1- and HES2-CMs have comparable trends and are collectively referred to as hESC-CMs.

		hESC-CMs	Fetal LVCMs	Adult LVCMs
Expression levels of Ca²⁺-handling proteins.	RyR	++	++	++++
	SERCA	+++	+++	++++
	Phospholamban	–	++	++++
	CSQ/Tdn/Jtn	–	+	++++
	Calreticulin	++++	++++	+
	NCX	+++	++++	+
Ca²⁺ transient properties	Basal [Ca ²⁺] _i	++	+++	++++
	Amplitude	++	++	++++
	Decay	++	++	++++
	Upstroke	++	++	++++